Spanish Hospital started clinical trial of CAR T-cells Against CD30 (HSP-CAR30) for Relapsed/ Refractory Hodgkin and T-cell Lymphoma
Photo by Sharon Pittaway
Spanish Hospital Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau is starting a new clinical trial of CAR T-cells Against CD30 (HSP-CAR30) for Relapsed/ Refractory Hodgkin and T-cell Lymphoma.
HSP-CAR30 is a cell suspension of genetically modified T-cells to express a second generation (4-1BBz) chimeric antigen receptor (CAR) directed against CD30.
The clinical trial started in September 29, 2020 and will continue throughout December 30, 2023.
Among Primary Outcome Measures are indicated:
- To assess safety and toxicity of the administration of autologous anti-CD30 CAR T-cells
- To establish the maximum tolerated dose (MTD; defined as the dose that induces maximum limiting toxicity) of autologous anti-CD30 CAR T-cells in patients with refractory or relapsed classic Hodgkin or CD30 + T NHL
- To analyze the rate of complete responses at 3 months after the procedure
Patients with the following pathologies:
- Performance status: ECOG 2-4
- Prior allogeneic haematopoietic stem cell transplant
- Active hepatitis B, C or HIV infection
- Active bacterial, fungal, or viral infection
- Evidence of CNS involvement by lymphoma.
are excluded from participation.
The contacts and locations are the Hospital Santa Creu i Sant Pau, Barcelona, Spain. For more details: https://ichgcp.net/clinical-trials-registry/NCT04653649
